Acquired MET exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer Journal Article

   

Authors:	Suzawa, K.; Offin, M.; Schoenfeld, A. J.; Plodkowski, A. J.; Odintsov, I.; Lu, D.; Lockwood, W. W.; Arcila, M. E.; Rudin, C. M.; Drilon, A.; Yu, H. A.; Riely, G. J.; Somwar, R.; Ladanyi, M.
Article Title:	Acquired MET exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer
Keywords:	targets; amplification; mutations; combination; crizotinib; t790m
Journal Title:	JCO Precision Oncology
Volume:	3
ISSN:	2473-4284
Publisher:	American Society of Clinical Oncology
Date Published:	2019-05-10
Language:	English
ACCESSION:	WOS:000470258400001
DOI:	10.1200/po.19.00011
PROVIDER:	wos
PMCID:	PMC6541452
PUBMED:	31157314
Notes:	Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/147796